Henan Newland Pharmaceutical Co. Ltd. A (301277) — Capital Reinvestment Ratio
Henan Newland Pharmaceutical Co. Ltd. A (301277) has a Capital Reinvestment Ratio of 0.87x as of December 2025, meaning it reinvests 1% of its operating cash flow (CN¥116.94 Million) in capital expenditures (CN¥101.38 Million). See Henan Newland Pharmaceutical Co. Ltd. A (301277) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Henan Newland Pharmaceutical Co. Ltd. A Capital Reinvestment Ratio (2020–2025)
This chart tracks Henan Newland Pharmaceutical Co. Ltd. A's Capital Reinvestment Ratio across 6 annual periods.
Annual Capital Reinvestment Ratio for Henan Newland Pharmaceutical Co. Ltd. A (2020–2025)
Year-by-year Capital Reinvestment Ratio for Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2025. For live market cap and broader valuation context, see Henan Newland Pharmaceutical Co. Ltd. A (301277) total market value.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.87x | CN¥116.94 Million | CN¥101.38 Million | ▼ -0.8% |
| 2024 | 0.87x | CN¥126.76 Million | CN¥110.79 Million | ▲ +135.0% |
| 2023 | 0.37x | CN¥259.46 Million | CN¥96.51 Million | ▼ -58.5% |
| 2022 | 0.90x | CN¥82.85 Million | CN¥74.34 Million | ▲ +73.4% |
| 2021 | 0.52x | CN¥49.08 Million | CN¥25.40 Million | ▲ +46.0% |
| 2020 | 0.35x | CN¥47.86 Million | CN¥16.96 Million | — |